HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ryutaro Asano Selected Research

Bispecific Antibodies

11/2021T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity.
1/2020Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach.
1/2017A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.
1/2015[Functionalization of Bispecific Therapeutic Antibodies Based on Protein Engineering].
9/2012A high-affinity gold-binding camel antibody: antibody engineering for one-pot functionalization of gold nanoparticles as biointerface molecules.
10/2011In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
1/2011Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
7/2006Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
12/2005[Construction history of bispecific antibodies and overview of its application for cancer immunotherapy].
4/2002Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ryutaro Asano Research Topics

Disease

31Neoplasms (Cancer)
11/2021 - 03/2002
5Carcinoma (Carcinomatosis)
07/2006 - 03/2002
1Colorectal Neoplasms (Colorectal Cancer)
01/2021
1Neurodegenerative Diseases (Neurodegenerative Disease)
12/2018
1Infections
04/2011
1Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
10/2007
1Burkitt Lymphoma (Burkitt's Lymphoma)
10/2007
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
10/2007
1Lymphoma (Lymphomas)
10/2007
1Leukemia
10/2007

Drug/Important Bio-Agent (IBA)

14ErbB Receptors (EGF Receptor)IBA
11/2021 - 04/2009
11Bispecific AntibodiesIBA
11/2021 - 03/2002
6AntibodiesIBA
11/2021 - 06/2004
5AntigensIBA
11/2021 - 03/2002
5Immunoglobulin G (IgG)IBA
01/2014 - 09/2007
4Proteins (Proteins, Gene)FDA Link
12/2018 - 03/2002
4Indicators and Reagents (Reagents)IBA
07/2006 - 03/2002
4Interleukin-2 (IL2)IBA
07/2006 - 03/2002
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2021 - 06/2004
2CytokinesIBA
01/2021 - 03/2005
2Interferon-gamma (Interferon, gamma)IBA
01/2021 - 02/2003
2Pharmaceutical PreparationsIBA
12/2018 - 03/2018
2Immunoglobulin FragmentsIBA
10/2013 - 07/2010
2Single-Chain AntibodiesIBA
10/2013 - 03/2002
2Membrane Proteins (Integral Membrane Proteins)IBA
10/2011 - 04/2009
2interleukin-21 (interleukin 21)IBA
10/2007 - 09/2002
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
06/2004 - 02/2003
2SuperantigensIBA
03/2002 - 03/2002
1Therapeutic UsesIBA
11/2021
1Granzymes (Granzyme)IBA
01/2021
1Peptide Hydrolases (Proteases)FDA Link
01/2021
1Amyloid (Amyloid Fibrils)IBA
12/2018
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2017
1Complementarity Determining Regions (Complementarity Determining Region)IBA
02/2013
1GoldIBA
09/2012
1Cetuximab (Erbitux)FDA Link
10/2011
1Fc Receptors (Fc Receptor)IBA
10/2011
1Epidermal Growth Factor (EGF)IBA
04/2011
1Interleukin-21 ReceptorsIBA
10/2007
1Biological ProductsIBA
03/2005
1Interleukin-12 (IL 12)IBA
03/2005
1Immunoglobulin Variable RegionIBA
03/2005
1Glycoproteins (Glycoprotein)IBA
03/2002
1Recombinant Fusion ProteinsIBA
03/2002

Therapy/Procedure

14Immunotherapy
11/2021 - 03/2002
7Therapeutics
11/2021 - 03/2002